Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment

The Hematology Journal : the Official Journal of the European Haematology Association
J BienvenuGroupe d'Etude des Lymphomes de l'Adulte

Abstract

In patients with low-grade non-Hodgkin's lymphoma, rituximab (MabThera) produces infusion-related toxicity, including fever, rigors, and chills in greater than 50% of those treated. The majority of these reactions are grade 1 or 2. In the GELA study LNH98-5, a total of 400 elderly patients with previously untreated diffuse large B-cell lymphoma were randomized to treatment with CHOP or with rituximab plus CHOP (R-CHOP). In a detailed investigation of biological events which may be associated with adverse reactions specific to rituximab infusion, a subgroup of 55 patients (26 in the CHOP group and 29 in the R-CHOP group) were selected for measurement of several biological parameters at baseline and at 1, 4 and 8 h (H1, H4 and H8, respectively) after commencing therapy. For 27 patients, measurements included cytokine and complement levels. Baseline demographic and disease characteristics were similar for patients in both treatment groups. Compared with the CHOP treatment group, patients in the R-CHOP group had significantly higher post-treatment changes in neutrophil, lymphocyte, and monocyte counts, LDH levels, C3a levels, and TNF-alpha levels. In the R-CHOP group, neutrophil levels increased at H4 (P<0.05), lymphocyte levels de...Continue Reading

Citations

Oct 10, 2008·Respiration; International Review of Thoracic Diseases·Adriano R TonelliP S Sriram
Oct 18, 2016·Drug Safety - Case Reports·Massimo CalderazzoLuca Gallelli
May 6, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kathy MillerLeonard Presta
Sep 17, 2004·Leukemia & Lymphoma·Lionel VédrineDidier Decaudin
Sep 24, 2005·Journal of Cutaneous Pathology·Yeshwant B RawalCynthia M Magro
Nov 22, 2005·International Journal of Hematology·Fadi I Jabr
May 4, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Elena CitteraJosée Golay
Jun 29, 2007·American Journal of Hematology·Stephanie A WagnerDamian A Laber
Dec 18, 2009·Anti-cancer Drugs·Maajid Mumtaz PeerzadaHamed A Daw
Dec 14, 2011·Rheumatology·Andreas V HadjinicolaouAndrew J K Ostör
Oct 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bertrand CoiffierUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma
Nov 18, 2004·Immunological Reviews·Mark J SmythYoshihiro Hayakawa
May 29, 2007·Oncogene·B Coiffier
Sep 1, 2012·Nuclear Medicine and Molecular Imaging·Prathamesh JoshiTapan Saikia
Jan 1, 2012·Translational Vision Science & Technology·Noriyasu HashidaKohji Nishida
Nov 12, 2015·European Clinical Respiratory Journal·Matiuallah NaqibullahElisabeth Bendstrup
Jun 27, 2003·The New England Journal of Medicine·Catherine BurtonRiaz Jan-Mohamed
Mar 15, 2008·Pharmacoepidemiology and Drug Safety·V GonzálezG Manso
Oct 5, 2006·The Korean Journal of Internal Medicine·Yuna LeeJae Hoon Lee
Aug 6, 2003·Blood·Theodora PapadakiAthanasios Fassas
Feb 18, 2011·The Cochrane Database of Systematic Reviews·Jasvinder A SinghRachelle Buchbinder
Feb 10, 2011·International Journal of Rheumatic Diseases·Petros EfthimiouAlissa Hersh
Feb 14, 2008·Internal and Emergency Medicine·Zaher K OtrockZiad M Salem
Feb 11, 2018·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Koichi KameiKenji Ishikura
Apr 11, 2018·Japanese Journal of Clinical Oncology·Toru TanakaAkihiko Gemma
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Nov 7, 2018·International Journal of Rheumatic Diseases·Khader N MustafaIsam K Bsisu
Jul 12, 2018·Expert Review of Anticancer Therapy·Li LiYohannes T Ghebre
Jul 11, 2012·Case Reports in Medicine·Ahmet B ErginHamed A Daw
Mar 27, 2015·Journal of Clinical Pharmacy and Therapeutics·J Tan, X Ni
Sep 11, 2003·The Lancet Oncology·Peter W Szlosarek, Frances R Balkwill

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

Current Opinion in Oncology
Guillaume Cartron, Philippe Solal-Céligny
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Chi Hoon MaengSun Lee
Bulletin du cancer
Jean-François TournamilleMaryse Lapeyre-Mestre
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Junshik HongJae Hoon Lee
Nature Clinical Practice. Nephrology
Mohammad SarrafRobert W Schrier
© 2022 Meta ULC. All rights reserved